Theravance Biopharma, Inc. (TBPH) - Stock Analysis
Last updated: Mar 9, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Theravance Biopharma benefits from record sales growth, upcoming Phase 3 CYPRESS data expected Q1 2026 as a key catalyst, positive technical momentum (+27% last month), and strong sector tailwinds, supporting near-term upside despite ongoing losses and high valuation.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Negative cashflow ⢠Elevated valuation By 2025-09-30 TBPH's liquidity and equity position strengthened materially (cash $175.6m, current ratio 9.48, working capital $317.3m) and leverage eased, but persistent operating losses, negative operating/free cash flow and a high valuation on very small quarterly revenue remain key risks.
Price Behavior
Key Price Behavior Insights: ⢠Sharp sell-off ⢠Gap lower ⢠Short-term support Support Level: $13.57 Resistance Level: $18.50â$20.50 Strong, momentum-driven decline last month (~30% drop) with an abrupt gap lower into early March that raises tail risk, while $13.57 is short-term support and reclaiming ~$18.5â$20.5 is needed to confirm a trend reversal.
Sentiment & News
Key News Insights: ⢠Phase 3 failure ⢠~60% cuts ⢠~$400M runway Theravance's Phaseâ3 ampreloxetine failure triggered an accelerated strategic review, ~60% operating cuts and potential sale while refocusing on YUPELRI despite a sharp stock selloff and roughly $400M cash runway. #cash-focusâ
AI Summary
TBPH's investment thesis has shifted from a binary, Phaseâ3 upside story to a cashâdriven, executionâdependent trade where nearâterm valuation now hinges on receiving the ~$100M Trelegy milestone, sustaining YUPELRI commercial growth under Viatris, and a valueârealizing strategic review rather than any internal R&D upside. Actionable steps: watch milestone recognition timing and next two YUPELRI sales printsâif the $100M lands and YUPELRI accelerates, reârate higher; if not, downside risk of financing or a lowâvalue sale is high.
Description
Theravance Biopharma is a biopharmaceutical company that researches, develops and commercializes respiratory medicines across the United States, Europe and Asia, with YUPELRI sold as a nebulized, once-daily therapy for COPD. Its clinical pipeline includes inhaled and gut-targeted small moleculesânotably several JAK inhibitors and other candidates addressing pulmonary and gastrointestinal disordersâalongside later-stage programs for autonomic and motility conditions. The company maintains licensing and collaboration agreements with major pharmaceutical partners and is incorporated in 2013 with headquarters in George Town, Cayman Islands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 5 | Dec 12 | TBPH | Theravance Biopharma, Inc. | Theravance Biopharma benefits from record sales growth, upcoming Phase 3 CYPRESS data expected Q1 2026 as a key catalyst, positive technical momentum (+27% last month), and strong sector tailwinds, supporting near-term upside despite ongoing losses and high valuation. | Closed | -2.1% |